文献速递认知障碍与痴呆

体内[18F]氟他西匹PET与阿尔茨海默病死后tau病理的相关性

Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology.
PubMed 文献 · JAMA Neurol · 2019-01-01

该病例研究对一名40余岁PSEN1突变所致阿尔茨海默病患者进行两次[18F]flortaucipir PET扫描,末次扫描后12个月行尸检定量tau病理。结果显示区域PET摄取与tau阳性神经突密度、胞体缠结及总tau负荷均显著相关,与β-淀粉样斑块无相关性。

要点

  • [18F]flortaucipir PET摄取与死后tau病理密度显著相关
  • PET摄取主要反映tau神经突和缠结负荷而非β-淀粉样病理
  • 该病例中临床病情快速进展伴皮层PET摄取年增20%至40%

核心结论

  • [18F]flortaucipir PET滞留是阿尔茨海默病总tau负荷的可靠体内测量指标。

研究设计与样本

  • 病例研究:一名40余岁PSEN1突变所致阿尔茨海默病男性患者,2015年5月至2016年12月于瑞典隆德大学医院接受2次[18F]flortaucipir PET扫描,末次扫描后12个月行尸检。

主要发现

  • 区域[18F]flortaucipir摄取与tau阳性神经突密度相关(AT8:rs=0.87,P<.001;Gallyas:rs=0.92,P<.001)。
  • 区域摄取与胞体tau缠结密度相关(AT8:rs=0.65,P=.01;Gallyas:rs=0.84,P<.001)。
  • 区域摄取与总tau负荷相关(AT8:rs=0.84,P<.001;Gallyas:rs=0.82,P<.001)。
  • [18F]flortaucipir与β-淀粉样病理之间未发现相关性。
  • 临床疾病症状在生前快速进展,许多皮层区域tau PET滞留年增20%至40%。

关键数值与推荐

  • tau病理采用磷酸化tau(AT8)免疫组化和Gallyas银染评估,并用体视学方法定量tau阳性神经突和胞体缠结密度。
  • β-淀粉样斑块采用4G8免疫组化检测。
  • 区域[18F]flortaucipir标准化摄取值比与相应脑区tau病理量进行比较。

临床怎么用

  • 对于阿尔茨海默病患者,[18F]flortaucipir PET可作为评估体内总tau负荷的影像学工具。
  • PET摄取解读时应聚焦tau病理而非β-淀粉样病理。

局限性

  • 本研究为单例病例报告,结果的外推性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In Alzheimer disease (AD), tau filaments form neuronal inclusions in neurites (neuropil threads) and in somata (neurofibrillary tangles), and neurite tau pathology constitutes the most common pathology. Positron emission tomography (PET) ligands have been developed to detect in vivo tau pathology in AD. However, the association of AD tau pathology post mortem with in vivo tau PET retention has not been established. Therefore, there is a need to investigate the associations of tau PET with postmortem tau pathology in AD. OBJECTIVE: To study the association of regional in vivo retention of the tau PET ligand [18F]flortaucipir (previously known as AV1451) with the density of tau neuropathology in the corresponding brain regions in a patient with AD. DESIGN, SETTING, AND PARTICIPANTS: The patient was a man in his 40s with AD caused by a PSEN1 mutation. Between May 2015 and December 2016, he underwent 2 [18F]flortaucipir PET scans at Lund University Hospital, Lund, Sweden. Postmortem analysis was performed 12 months after the last PET scan. Tau pathology was assessed using phosphorylated tau (AT8) immunohistochemistry and Gallyas silver staining. In addition to the regional total tau pathology burden, the density of tau-positive neurites and intrasomal tau tangles were quantified using a stereology-based method. Further, β-amyloid-containing plaques were detected using 4G8 immunohistochemistry. Data were analyzed between January 2018 and August 2018. MAIN OUTCOMES AND MEASURES: Regional standardized uptake value ratios of [18F]flortaucipir were compared with the amount of tau pathology in the corresponding brain areas. RESULTS: In this patient, the clinical disease symptoms progressed rapidly in life, paralleled with an annual increase of tau PET retention of 20% to 40% in many cortical regions. Compared with postmortem immunohistochemistry, regional in vivo uptake of [18F]flortaucipir was correlated with the density of tau-positive neurites (AT8: rs = 0.87; P < .001; Gallyas: rs = 0.92; P < .001), intrasomal tau tangles (AT8: rs = 0.65; P = .01; Gallyas: rs = 0.84; P < .001), and total tau burden (AT8: rs = 0.84; P < .001; Gallyas: rs = 0.82; P < .001). No correlations between [18F]flortaucipir and β-amyloid pathology were found. CONCLUSIONS AND RELEVANCE: These results indicate that [18F]flortaucipir PET retention is a robust in vivo measure of the total AD tau burden.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Smith R, Wibom M, Pawlik D, et al. Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology. JAMA Neurol. 2019. PMID: 30508025. doi:10.1001/jamaneurol.2018.3692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。